FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy

NCT04491084 PHASE1, PHASE2 TERMINATED Results posted

The purpose of this study is to test a new way of treating the most common form of lung cancer. The investigators are testing a combination of radiotherapy with two new forms of immunotherapy. This study is testing the safety and effectiveness of this treatment approach as compared to standard treatment options.

Details

Lead sponsor	Albert Einstein College of Medicine
Phase	PHASE1, PHASE2
Status	TERMINATED
Enrolment	5
Start date	Fri Jan 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Aug 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Non Small Cell Lung Cancer
• Lung Cancer

Interventions

• FLT3 Ligand (CDX-301)
• anti-CD40 antibody (CDX-1140)
• SBRT

Countries

United States